Biomm

Biomm FCF Growth

The Year-over-Year Free Cash Flow Growth of Biomm (BIOM3.SA) as of Nov 7, 2026 is -24.77 %. In the previous year, Year-over-Year Free Cash Flow Growth was -37.03 % — a change of -33.10% (higher).

FCF Growth

-24.77 %

YoY

-33.10%

Last updated:

Year-over-Year Free Cash Flow Growth of Biomm is 2025 -24.77 % . Year-over-Year Free Cash Flow Growth of Biomm was 2024 -37.03 % . It decreases by -33.10% higher compared to the previous year.

The Biomm FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
25.22 BRL
Jan 1, 2019
-88.69 BRL
Jan 1, 2020
-19.47 BRL
Jan 1, 2021
0.27 BRL
Jan 1, 2022
32.39 BRL
Jan 1, 2023
-18.37 BRL
Jan 1, 2024
-37.03 BRL
Jan 1, 2025
-24.77 BRL
The Biomm FCF Growth history
YEARFCF GrowthYoY
-24.77 %-33.10%
-37.03 %+101.62%
-18.37 %-156.70%
32.39 %+11,855.30%
0.27 %-101.39%
-19.47 %-78.04%
-88.69 %-451.61%
25.22 %-37.93%
40.64 %-136.82%
-110.39 %+878.63%
-11.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Year-over-Year Free Cash Flow Growth of Biomm is -24.77 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Biomm since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biomm

All Key Metrics — Biomm